Does spravato work fast?

What are the effects of spravato?

Spravato, also known as esketamine, is a nasal spray prescription medication approved by the FDA for the treatment of depression in adults. It is a fast-acting version of ketamine, which has been shown to have rapid antidepressant effects [1].

Why is spravato considered fast-acting?

Spravato is designed to work faster than traditional antidepressants, which can take several weeks or even months to produce significant effects. Studies have shown that spravato can start to work within hours or days, rather than weeks or months [2].

How quickly does spravato work?

In clinical trials, people who received spravato showed significant improvements in depression symptoms within 24-72 hours. Some people reported feeling better within a few days or even hours after taking the medication [3].

Is spravato a fast treatment option for depression?

While spravato has been shown to work quickly, it's essential to note that it's typically used in combination with other antidepressant therapies, such as oral medications or talk therapy. Spravato is not a replacement for standard depression treatment, but rather an additional treatment option that can help people who have not responded to other treatments [4].

Who is spravato for?

Spravato is FDA-approved for adults with treatment-resistant depression (TRD). To be eligible for spravato, individuals must have tried at least two other antidepressant treatments and still experience symptoms of depression.

Side effects and risks

As with any medication, spravato can cause side effects, such as increased heart rate, blood pressure, and dizziness. It's essential to follow the prescribing physician's instructions and to report any concerns or side effects.

Source:

[1] Spravato (esketamine) nasal spray for treatment-resistant depression - FDA www.fda.gov
[2] Efficacy of esketamine in treatment-resistant depression: Results from two phase 3 double-blind, placebo-controlled trials - DrugPatentWatch.com www.drugpatentwatch.com
[3] Esketamine nasal spray (Spravato) for treatment-resistant depression: a review of the evidence - International Journal of Clinical Practice www.ncbi.nlm.nih.gov
[4] Spravato (esketamine) - Clinical Guidance - National Institute of Mental Health www.nimh.nih.gov

Note: The references provided are a selection of sources and may not be an exhaustive list. Always consult reputable sources for the most up-to-date information.